We are live on !
Find out more
EntryPoint Capital Portfolio holdings
AUM
$412M
Turnover
50.4%
1-Year Est. Return
28.52%
This Fund
S&P 500
This Quarter Est. Return
+15.49%
1 Year Est. Return
+28.52%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$412M
AUM Growth
+$70.8M
(+21%)
Cap. Flow
+$36.5M
Cap. Flow % of AUM
Cap. Flow %
8.87%
Top 10 Holdings %
Top 10 Hldgs %
4.34%
Holding
1,002
New
271
Increased
170
Reduced
168
Closed
234
Avg Time Held
0.4
years
Top 10 Avg Time Held
0
years
Top 20 Avg Time Held
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Huntington Bancshares
HBAN
|
+$1.67M |
| 2 |
Donaldson
DCI
|
+$1.6M |
| 3 |
FedEx
FDX
|
+$1.6M |
| 4 |
Fidelity National Financial
FNF
|
+$1.53M |
| 5 |
Graco
GGG
|
+$1.51M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cadence Design Systems
CDNS
|
+$1.48M |
| 2 |
TIC Solutions Inc
TIC
|
+$1.48M |
| 3 |
Schrodinger
SDGR
|
+$1.27M |
| 4 |
Exelon
EXC
|
+$1.23M |
| 5 |
Visteon
VC
|
+$1.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 18% |
| 2 | Financials | 16.8% |
| 3 | Healthcare | 15.07% |
| 4 | Technology | 12.86% |
| 5 | Consumer Discretionary | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
751
Emergent Biosolutions
EBS
$322M
| $87.1K | 0.02% |
10,390
-4,187
| -29% | -$35K |
2026 Q1
1 quarter
|
|
752
VTEX
VTEX
$680M
| $85K | 0.02% |
21,257
| – | – |
2024 Q4
6 quarters
|
|
753
Telos
TLS
$343M
| $77.9K | 0.02% |
16,931
-24,620
| -59% | -$109K |
2026 Q1
1 quarter
|
|
754
Foghorn Therapeutics
FHTX
$120M
| $75.6K | 0.02% |
+15,483
| New | +$68.7K |
2026 Q2
0 quarters
|
|
755
Protara Therapeutics
TARA
$152M
| $73.7K | 0.02% |
+19,286
| New | +$91.7K |
2026 Q2
0 quarters
|
|
756
Borr Drilling
BORR
$1.29B
| $69.6K | 0.02% |
16,862
| – | – |
2025 Q2
4 quarters
|
|
757
Village Farms International
VFF
$336M
| $64.5K | 0.02% |
32,263
-12,224
| -27% | -$30.6K |
2025 Q4
2 quarters
|
|
758
Coty
COTY
$2.78B
| $61.8K | 0.02% |
28,602
-132,708
| -82% | -$286K |
2026 Q1
1 quarter
|
|
759
Wipro
WIT
$21.1B
| $61.4K | 0.01% |
27,280
-54,660
| -67% | -$116K |
2025 Q1
5 quarters
|
|
760
Real REMAX Group Inc. Common Stock
REAX
$339M
| $59.1K | 0.01% |
3,249
+1,258
| +63% | +$25.6K |
2025 Q3
3 quarters
|
|
761
enCore Energy
EU
$159M
| $58.4K | 0.01% |
44,615
-9,913
| -18% | -$16.7K |
2025 Q4
2 quarters
|
|
762
Cadiz
CDZI
$335M
| $58.4K | 0.01% |
+13,981
| New | +$62.3K |
2026 Q2
0 quarters
|
|
763
Fossil Group
FOSL
$416M
| $53K | 0.01% |
+12,810
| New | +$57.4K |
2026 Q2
0 quarters
|
|
764
Ambev
ABEV
$51.2B
| $50.8K | 0.01% |
16,169
| – | – |
2025 Q4
2 quarters
|
|
765
Snap
SNAP
$10.9B
| $48.7K | 0.01% |
+10,961
| New | +$59.9K |
2026 Q2
0 quarters
|
|
766
Community Health Systems
CYH
$399M
| $39.8K | 0.01% |
11,916
-60,418
| -84% | -$178K |
2024 Q4
6 quarters
|
|
767
Brandywine Realty Trust
BDN
$467M
| $39K | 0.01% |
12,302
| – | – |
2024 Q4
6 quarters
|
|
768
Coherus Oncology
CHRS
$158M
| $34.1K | 0.01% |
+24,377
| New | +$39.8K |
2026 Q2
0 quarters
|
|
769
Apple
AAPL
$5.01T
| – | – |
-1,162
| Closed | -$295K | – |
|
770
AbbVie
ABBV
$500B
| – | – |
-2,913
| Closed | -$634K | – |
|
771
Axcelis
ACLS
$3.62B
| – | – |
-3,213
| Closed | -$299K | – |
|
772
Aclaris Therapeutics
ACRS
$567M
| – | – |
-33,007
| Closed | -$124K | – |
|
773
Analog Devices
ADI
$197B
| – | – |
-1,060
| Closed | -$337K | – |
|
774
Adaptive Biotechnologies
ADPT
$4.04B
| – | – |
-20,517
| Closed | -$285K | – |
|
775
American Electric Power
AEP
$69.6B
| – | – |
-1,543
| Closed | -$202K | – |
|
Similar funds
EntryPoint Capital's Q2 2026 Portfolio in Review
As of Q2 2026, EntryPoint Capital held 1,002 positions worth $412M, up 21% from $341M the previous quarter. Its ten largest holdings account for 4.3% of the portfolio.
EntryPoint Capital deployed $36.5M of net new capital in Q2 2026, opening 271 new positions and adding to 170 existing holdings. Its largest new stake was Huntington Bancshares: 101,010 shares worth $1.79M.
By sector, the portfolio is most concentrated in Industrials at 18% of assets, down from 19% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Cadence Design Systems, an estimated $1.48M trimmed.
- EntryPoint Capital's largest Q2 2026 buy was Huntington Bancshares: 101,010 shares worth $1.79M.
- EntryPoint Capital added most to Gilead Sciences in Q2 2026, an estimated $1.51M increase.
- EntryPoint Capital's biggest Q2 2026 reduction was Cadence Design Systems, cutting an estimated $1.48M.
- EntryPoint Capital fully exited Exelon in Q2 2026, selling an estimated $1.23M.
- EntryPoint Capital's ten largest holdings make up 4.3% of its $412M portfolio in Q2 2026.
- EntryPoint Capital opened 271 new positions and closed 234 in Q2 2026.
- EntryPoint Capital's portfolio value rose 21% quarter-over-quarter to $412M.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.